Systemic sclerosis is a multisystemic autoimmune disease characterized by vasculopathy and fibrosis. Racial factors exert a significant influence on the epidemiology, clinical manifestations, antibody profile, mortality and genetic factors in systemic sclerosis. In this review, we examined Asian systemic sclerosis cohorts reported in Asia and multi-racial cohort studies to evaluate the disease characteristics and outcomes of systemic sclerosis in Asians. Asian patients have distinct genetic susceptibility to systemic sclerosis, younger age of systemic sclerosis onset, higher frequency of diffuse skin involvement, different autoantibody profiles such as higher frequency of anti-Scl70 and anti-U1-RNP antibodies, and more severe clinical phenotype. There was a suggestion of poorer survival among Asians that may be contributed by more severe disease, socioeconomic factors and differences in healthcare systems. Recognizing the influence of racial differences in systemic sclerosis disease course is important as it has implications for appropriate treatment, monitoring and prognostication.
ReveilleJD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep2003; 5(2): 160–167.
2.
ChungMPDontsiMPostlethwaiteD, et al. Increased mortality in Asians with systemic sclerosis in Northern California. ACR Open Rheumatol2020; 2(4): 197–206.
3.
JaegerVKTiklyMXuD, et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology2020; 59(7): 1684–1694.
4.
ProudmanSMHuqMStevensW, et al. What have multicentre registries across the world taught us about the disease features of systemic sclerosis?J Scleroderma Relat Disord2017; 2(3): 169–182.
5.
HashimotoATejimaSTonoT, et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol2011; 38(9): 1931–1939.
6.
MoonKWLeeSSLeeYJ, et al. Clinical and laboratory characteristics and mortality in Korean patients with systemic sclerosis: a nationwide multicenter retrospective cohort study. J Rheumatol2018; 45(9): 1281–1288.
7.
LiXQianYQLiuN, et al. Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study. Clin Rheumatol2018; 37(11): 3051–3056.
8.
HuSHouYWangQ, et al. Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. Arthritis Res Ther2018; 20(1): 235.
9.
WangkaewSPrasertwitayakijNPhrommintikulA, et al. Causes of death, survival and risk factors of mortality in Thai patients with early systemic sclerosis: inception cohort study. Rheumatol Int2017; 37(12): 2087–2094.
10.
FoocharoenCPeansukwechUMahakkanukrauhA, et al. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: a cohort study. Int J Rheum Dis2020; 23(7): 945–957.
11.
SantosaATanCSTengGG, et al. Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. Scand J Rheumatol2016; 45(6): 499–506.
12.
KuoCFSeeLCYuKH, et al. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol2011; 40(5): 373–378.
13.
JanardanaRNairAMSurinAK, et al. Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?Clin Rheumatol2019; 38(11): 3179–3187.
14.
PoormoghimHAndalibEJalaliA, et al. Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran. Rheumatol Int2016; 36(7): 925–934.
15.
BairkdarMRossidesMHesselstrandR, et al. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology2021; 60(7): 3121–3133.
16.
TamakiTMoriSTakeharaK. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res1991; 283(6): 366–371.
17.
KuoCFLuoSFYuKH, et al. Familial risk of systemic sclerosis and co-aggregation of autoimmune diseases in affected families. Arthritis Res Ther2016; 18(1): 231.
18.
OtaYKuwanaM. Updates on genetics in systemic sclerosis. Inflamm Regen2021; 41(1): 17.
19.
ReveilleJDDurbanEMacLeod-St ClairMJ, et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest1992; 90(3): 973–980.
20.
ZhouXLeeJEArnettFC, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum2009; 60(12): 3807–3814.
21.
KuwanaMInokoHKamedaH, et al. Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med1999; 38(4): 336–344.
22.
ArnettFCGourhPSheteS, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis2010; 69(5): 822–827.
23.
GilchristFCBunnCFoleyPJ, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun2001; 2(2): 76–81.
24.
WangJGuoXYiL, et al. Association of HLA-DPB1 with scleroderma and its clinical features in Chinese population. PLoS ONE2014; 9(1): e87363.
25.
LouthrenooWKasitanonNWichainunR, et al. Association of HLA-DRB1*15:02 and DRB5*01:02 allele with the susceptibility to systemic sclerosis in Thai patients. Rheumatol Int2013; 33(8): 2069–2077.
26.
HeDWangJYiL, et al. Association of the HLA-DRB1 with scleroderma in Chinese population. PLoS ONE2014; 9(9): e106939.
27.
KangSHParkMHSongEY, et al. Association of HLA class II genes with systemic sclerosis in Koreans. J Rheumatol2001; 28(7): 1577–1583.
28.
Al-SheikhHAhmadZJohnsonSR. Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality. J Rheumatol2019; 46(9): 1103–1108.
29.
LowAHJohnsonSRLeeP. Ethnic influence on disease manifestations and autoantibodies in Chinese-descent patients with systemic sclerosis. J Rheumatol2009; 36(4): 787–793.
30.
WalkerUATyndallACzirjákL, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis2007; 66(6): 754–763.
31.
WangJAssassiSGuoG, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol2013; 32(5): 617–621.
32.
LowAHLTengGGLawWG, et al. Disease characteristics of the Singapore Systemic Sclerosis Cohort. Proc Singap Healthc2013; 22(1): 8–14.
33.
HoKTReveilleJD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther2003; 5(2): 80–93.
34.
HamaguchiYHasegawaMFujimotoM, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol2008; 158(3): 487–495.
35.
MeyerODe ChaisemartinLNicaise-RolandP, et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol2010; 37(1): 125–130.
36.
PradhanVRajadhyakshaANadkarM, et al. Clinical and autoimmune profile of scleroderma patients from Western India. Int J Rheumatol2014; 2014: 983781.
37.
QiuMNianXPangL, et al. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: a systematic review and meta-analysis. Int J Rheum Dis2021; 24: 1449–1459.
38.
MeierFMFrommerKWDinserR, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis2012; 71(8): 1355–1360.
39.
ReveilleJDFischbachMMcNearneyT, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum2001; 30(5): 332–346.
40.
MukerjeeDSt GeorgeDColeiroB, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis2003; 62(11): 1088–1093.
41.
Rubio-RivasMHomsNACuarteroD, et al. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: systematic review and meta-analysis. Autoimmun Rev2021; 20(1): 102713.
42.
HuangJLiMTianZ, et al. Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China. Clin Exp Rheumatol2014; 32(6, Suppl. 86): S115–S121.
43.
MichelfelderMBeckerMRiedlingerA, et al. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol2017; 36(2): 381–390.
44.
CondliffeRKielyDGPeacockAJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med2009; 179(2): 151–157.
45.
NovianiMSaffariSETanJL, et al. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort. Semin Arthritis Rheum2020; 50(3): 473–479.
46.
LambovaS. Cardiac manifestations in systemic sclerosis. World J Cardiol2014; 6(9): 993–1005.
47.
KahanACoghlanGMcLaughlinV. Cardiac complications of systemic sclerosis. Rheumatology2009; 48(Suppl. 3): iii45–iii48.
48.
ElhaiMMeuneCAvouacJ, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology2012; 51(6): 1017–1026.
49.
SallamHMcNearneyTAChenJD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther2006; 23(6): 691–712.
50.
BeckerMORiemekastenG. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol2016; 12(2): 115–135.
51.
MouthonLBéreznéABussoneG, et al. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol2011; 40(2): 84–91.
52.
TurkMPopeJE. The frequency of scleroderma renal crisis over time: a metaanalysis. J Rheumatol2016; 43(7): 1350–1355.
53.
WangkaewSLertthanaphokSPuntanaS, et al. Risk factors and outcome of Thai patients with scleroderma renal crisis: a disease duration-matched case control study. Int J Rheum Dis2017; 20(10): 1562–1571.
54.
Rubio-RivasMRoyoCSimeónCP, et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum2014; 44(2): 208–219.
55.
TyndallAJBannertBVonkM, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis2010; 69(10): 1809–1815.
